Table 3.
Effect of eRegistry's clinical decision support on process outcomes of screening and management of conditions during antenatal care and health outcomes at delivery
| Control group*(n=3148) | Intervention group*(n=3219) | Adjusted odds ratio (95% CI)† | |
|---|---|---|---|
| Anaemia | |||
| Screening and management during eligible antenatal contacts | 1535/5320 (28·8%) | 2297/5182 (44·3%) | 1·88 (1·52–2·32) |
| Screening during eligible contacts | 1434/4513 (31·7%) | 2159/4407 (48·9%) | .. |
| Management of anaemia | 101/807 (12·5%) | 138/775 (17·8%) | .. |
| Diabetes | |||
| Screening and management during eligible antenatal contacts | 1726/4348 (39·7%) | 2189/4321 (50·7%) | 1·45 (1·14–1·83) |
| Screening during eligible contacts | 1714/4318 (39·6%) | 2182/4279 (50·9%) | .. |
| Management of diabetes | 12/30 (40%) | 7/42 (17%) | .. |
| Hypertension | |||
| Screening and management during eligible antenatal contacts | 7555/7982 (94·7%) | 7314/7569 (96·6%) | 1·62 (1·29–2·05) |
| Screening during eligible contacts | 7536/7884 (95·6%) | 7266/7470 (97·3%) | .. |
| Management of hypertension | 19/98 (19·4%) | 48/99 (48·5%) | .. |
| Abnormal foetal growth | |||
| Screening and management during eligible antenatal contacts | 394/500 (78·8%) | 458/665 (68·9%) | 0·59 (0·37–0·96) |
| Screening during eligible contacts | 386/467 (82·6%) | 450/610 (73·7%) | .. |
| Management of abnormal foetal growth | 8/33 (24·2%) | 8/55 (14·5%) | .. |
Data are n/N (%), unless otherwise stated.
*
Unadjusted.
†
Adjusted for clustering and for repeated antenatal care visits by a woman.